Mode
Text Size
Log in / Sign up

Narrative review discusses eosinophil abundance associations with lung cancer prognosis and immunotherapy responseHigh eosinophil counts in lung cancer tumors may signal better responses to immune therapy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider eosinophil abundance as a potential biomarker for immune checkpoint inhibitor response in lung cancer.

This narrative review synthesizes evidence regarding eosinophil abundance in tumor tissues and peripheral blood within the context of lung cancer. The scope encompasses anti-tumor immunity, tumor progression, prognostic outcomes, and response to immune checkpoint inhibitors. The authors do not report specific sample sizes, settings, or follow-up durations for the included data sources.

Key findings indicate that eosinophil abundance is associated with both favorable and unfavorable prognostic outcomes. Specifically, elevated eosinophil counts correlate with improved responses to immune checkpoint inhibitors. However, the review notes that effect sizes, absolute numbers, and p-values are not reported in the source material. The direction of association for general prognostic outcomes is not specified beyond the dualistic nature of the findings.

Significant limitations are acknowledged by the authors. Distinctions between tumor-infiltrating and circulating eosinophils remain incompletely understood. Additionally, the dualistic roles of eosinophils in metastasis and immune modulation remain incompletely understood. These gaps suggest that the evidence base is not yet definitive for clinical application.

Regarding practice relevance, the review underscores the promise of eosinophils as diagnostic and therapeutic targets in precision immuno-oncology. Clinicians should note that the authors advise against inferring causation from association. No adverse events or safety data were reported in this review.

Lung cancer patients face a complex battle where their own immune system sometimes fails to stop the disease. A recent narrative review explores a specific white blood cell called an eosinophil, which lives in both the blood and the tumor itself. This review looks at how these cells might help or hinder the fight against cancer.

The findings suggest that having more eosinophils in the tumor and blood often connects to better responses to immune checkpoint inhibitors. These drugs help the body recognize and attack cancer cells more effectively. When eosinophil levels are higher, patients may see improved outcomes in fighting tumor progression and achieving better prognostic results.

However, the picture is not entirely clear yet. The review notes that scientists do not fully understand the different roles these cells play in spreading cancer versus boosting the immune system. Because the study is a review of existing data rather than a new trial, it cannot prove that changing eosinophil levels will cure cancer. Still, these cells show promise as potential targets for future precision treatments.

What this means for you:
Higher eosinophil counts in lung cancer tumors may predict better responses to immune checkpoint inhibitors.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Eosinophils, traditionally viewed as effector cells in allergic and parasitic responses, have emerged as multifaceted regulators within the tumor microenvironment (TME). In lung cancer, eosinophils demonstrate complex and context-dependent functions, shaped by chemokines, cytokines, and tumor-derived signals such as CCL11 and IL-33. Recent studies indicate that eosinophils may either promote anti-tumor immunity, by enhancing CD8+ T cell infiltration, secreting cytotoxic granules, and cooperating with IL-33, or facilitate tumor progression through recruitment of regulatory T cells, immune suppression, and expression of immunoregulatory enzymes like IDO. Moreover, eosinophil abundance in tumor tissues and peripheral blood has been associated with both favorable and unfavorable prognostic outcomes in lung cancer patients. Notably, elevated eosinophil counts correlate with improved responses to immune checkpoint inhibitors (ICIs), positioning them as potential biomarkers for immunotherapy efficacy. However, distinctions between tumor-infiltrating and circulating eosinophils, as well as their dualistic roles in metastasis and immune modulation, remain incompletely understood. This review summarizes current advances in understanding eosinophil biology in lung cancer and underscores their promise as diagnostic and therapeutic targets in precision immuno-oncology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.